Spyre Therapeutics
Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.
$90.05
After-hours close−0.31 (−0.34%)
At close$90.36(−3.48%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.80 | — | — |
| Aug 2026 | −$0.76 | −$0.36 | +52.6% |
| May 2026 | −$0.66 | −$0.74 | −12.1% |
| Feb 2026 | −$0.66 | −$0.70 | −6.1% |
| Nov 2025 | −$0.68 | −$0.15 | +77.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.80 | — | — | — | — | — |
| Aug 4, 2026 | −$0.76 | −$0.36 | +52.6% | — | — | — |
| May 5, 2026 | −$0.66 | −$0.74 | −12.1% | — | — | — |
| Feb 19, 2026 | −$0.66 | −$0.70 | −6.1% | $142.9M | $90.5M | −36.7% |
| Nov 4, 2025 | −$0.68 | −$0.15 | +77.9% | — | — | — |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 5, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 29, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 11, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 30, 2022 | ||||||
| Sep 29, 2022 | ||||||
| Jun 29, 2022 | ||||||
| Mar 30, 2022 | ||||||
| Dec 30, 2021 | ||||||
| Sep 29, 2021 | ||||||
| Jun 29, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 30, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||
| Dec 30, 2018 | ||||||
| Sep 30, 2018 | ||||||
| Jun 30, 2018 | ||||||
| Mar 31, 2018 | ||||||
| Dec 30, 2017 | ||||||
| Sep 30, 2017 | ||||||
| Jun 30, 2017 | ||||||
| Mar 31, 2017 | ||||||
| Dec 30, 2016 | ||||||
| Sep 30, 2016 | ||||||
| Jun 30, 2016 | ||||||
| Mar 31, 2016 | ||||||
| Dec 31, 2015 | ||||||
| Sep 30, 2015 | ||||||
| Jun 30, 2015 | ||||||